News | Coronavirus (COVID-19) | March 29, 2022

Second Booster Approved as Option for Additional Protection Against COVID-19

The American Heart Association/American Stroke Association released a statement about the approved use of a second COVID-19 booster for certain immunocompromised individuals, including heart transplant patients

Today the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) approved the use of a second COVID-19 booster shot for adults over age 50 and certain immunocompromised individuals, including heart transplant patients.

Getty Images


March 29, 2022 — Today the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) approved the use of a second COVID-19 booster shot for adults over age 50 and certain immunocompromised individuals, including heart transplant patients. While not issuing a direct recommendation, the agencies instead issued emergency authorization for a fourth shot of the Pfizer-BioNTech or Moderna vaccines to provide additional protection against the coronavirus and its variants for certain people. The American Heart Association continues to align with guidance from the CDC, the nation’s pandemic control experts, and supports the use of this fourth shot, as indicated.

According to the CDC, the additional booster should be given at least four months after the initial booster. There is still little research on the use of a fourth dose of the vaccine, however, emerging evidence finds the effectiveness against COVID-19 and its variants may start to diminish three to six months after receipt of an initial booster dose.

The American Heart Association/American Stroke Association, a global force for longer, healthier lives for all, remains concerned about the continuing gaps in COVID-19 vaccination among people from all eligible age groups in the U.S., including people from diverse racial and ethnic groups and pregnant people.

“Individuals eligible for COVID vaccination who are not yet fully immunized are urged get the series of vaccines at least up through the first booster. People who are eligible for the second booster should call their clinical care office to discuss the need for a second booster,” said American Heart Association volunteer President Donald M. Lloyd-Jones, M.D., Sc.M., FAHA, chair of the department of preventive medicine, the Eileen M. Foell Professor of Heart Research and professor of preventive medicine, medicine and pediatrics at Northwestern University’s Feinberg School of Medicine in Chicago. “It is also important to ensure you are up to date on controlling other health issues including any cardiovascular risk factors, such as obesity, hypertension, and diabetes, that can put you at increased risk for heart disease, stroke and COVID-19.”

For more information: www.heart.org/covid19

Related COVID-19 Cardiology Content:

American Heart Association Supports COVID Vaccine Boosters Suggested by the CDC

The Long-term Cardiovascular Impact of COVID-19

COVID-19 Changes Properties Blood Cells

VIDEO: Antithrombotic Prophylaxis in COVID-19 Patients — Interview with Behnood Bikdeli M.D.

Coronavirus Disease 2019 (COVID-19) and the Heart—Is Heart Failure the Next Chapter?

PHOTO GALLERY: How COVID-19 Appears on Medical Imaging

Heart Damage Found in More Than Half of COVID-19 Patients Discharged From Hospitals

Overview of Randomized Trials of Antithrombotic Therapy for COVID-19 Patients 

COVID-19 Can Kill Heart Cells and Interfere With Contraction


Related Content

News | AHA

November 15, 2022 — Telehealth is a proven and valuable option for people with cardiovascular disease, however, there ...

Home November 15, 2022
Home
News | AHA

November 14, 2022 — The American Hospital Association Scientific Sessions 2022, held Nov. 5-7 in Chicago, IL, presented ...

Home November 14, 2022
Home
News | AHA

November 10, 2022 ­– Significant findings from the clinical trial, known as “BEST-CLI — Best Endovascular versus Best ...

Home November 10, 2022
Home
Feature | AHA

November 9, 2022 — Seven awardees were honored during the American Heart Association Scientific Sessions (AHA 2022). The ...

Home November 09, 2022
Home
News | AHA

November 8, 2022 — Genomic-based therapies for cardiovascular disease are emerging fast in research, and could soon be ...

Home November 08, 2022
Home
News | AHA

November 8, 2022 — After hospital discharge for heart failure, people treated with either loop diuretic medication ...

Home November 08, 2022
Home
News | AHA

November 8, 2022 — A single IV infusion of NTLA-2001, a novel CRISPR/Cas9-based gene editing therapy, significantly ...

Home November 08, 2022
Home
News | AHA

November 8, 2022 — iRhythm Technologies, Inc., a leading cardiovascular diagnostics and digital healthcare solutions ...

Home November 08, 2022
Home
News | AHA

November 7, 2022 — HeartFlow, Inc., the leader in revolutionizing precision heartcare, today announced new trial results ...

Home November 07, 2022
Home
News | AHA

November 7, 2022 — iRhythm Technologies, Inc., a leading cardiovascular diagnostics and digital healthcare solutions ...

Home November 07, 2022
Home
Subscribe Now